This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rite Aid Reports Same Store Sales For July

Rite Aid Corporation (NYSE: RAD) today announced sales results for July.

Monthly Sales

For the four weeks ended July 27, 2013, same store sales increased 1.3 percent over the prior-year period. July front-end same store sales increased 0.7 percent. Pharmacy same store sales, which included an approximate 307 basis points negative impact from new generic introductions, increased 1.6 percent. Prescription count at comparable stores increased 0.4 percent over the prior-year period.

Total drugstore sales for the four-week period increased 0.9 percent to $1.898 billion compared to $1.881 billion for the same period last year. Prescription sales accounted for 67.7 percent of drugstore sales, and third party prescription sales represented 97.0 percent of pharmacy sales.


Same store sales for the 21-week period ended July 27, 2013 decreased 1.2 percent over the prior-year period. Front-end same store sales increased 0.4 percent while pharmacy same store sales decreased 1.9 percent. Prescription count at comparable stores was flat compared to the prior-year period.

Total drugstore sales for the 21 weeks ended July 27, 2013 decreased 1.5 percent with sales of $10.089 billion compared to $10.247 billion for the same period last year. Prescription sales represented 67.5 percent of total drugstore sales, and third party prescription sales represented 97.0 percent of pharmacy sales.

Rite Aid is one of the nation’s largest drugstore chains. On July 27, 2013, the company operated 4,611 stores compared to 4,646 stores in the like period a year ago. Information about Rite Aid, including corporate background and press releases, is available through the company’s website at Note that all sales data in this release is preliminary, unaudited and subject to revision.

Statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties that are described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in other documents that we file or furnish with the Securities and Exchange Commission, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Rite Aid expressly disclaims any current intention to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs